These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 26738756)

  • 1. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
    Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
    J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Berends SE; Strik AS; Jansen JM; de Boer NK; van Egmond PS; Brandse JF; Mathôt RA; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Jun; 54(6):700-706. PubMed ID: 31132014
    [No Abstract]   [Full Text] [Related]  

  • 6. Golimumab for moderate to severe ulcerative colitis.
    Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit.
    Hyams JS; Chan D; Adedokun OJ; Padgett L; Turner D; Griffiths A; Veereman G; Heyman MB; Rosh JR; Wahbeh G; Strauss R
    Inflamm Bowel Dis; 2017 Dec; 23(12):2227-2237. PubMed ID: 29140944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
    Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
    Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
    Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
    Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
    Brandse JF; van den Brink GR; Wildenberg ME; van der Kleij D; Rispens T; Jansen JM; Mathôt RA; Ponsioen CY; Löwenberg M; D'Haens GR
    Gastroenterology; 2015 Aug; 149(2):350-5.e2. PubMed ID: 25917786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.
    Detrez I; Schops G; Lefrère J; Tops S; Van Assche G; Vermeire S; Van Moerkercke W; Ferrante M; Gils A
    AAPS J; 2018 Dec; 21(1):10. PubMed ID: 30564993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
    Samaan MA; Cunningham G; Tamilarasan AG; Beltran L; Pavlidis P; Ray S; Mawdsley J; Anderson SH; Sanderson JD; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2020 Jul; 52(2):292-302. PubMed ID: 32506695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.
    Adedokun OJ; Gunn GR; Leu JH; Gargano C; Xu Z; Sandborn WJ; Rutgeerts P; Shankar G
    Inflamm Bowel Dis; 2019 Aug; 25(9):1532-1540. PubMed ID: 30753466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
    Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
    Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
    Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
    Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
    Vande Casteele N; Khanna R
    Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study.
    Berger AE; Duru G; de Vries A; Marini JC; Aoucheta D; Cornillie F; Nancey S; Detrez I; Gils A; Roblin X; Paul S
    Ther Drug Monit; 2019 Aug; 41(4):459-466. PubMed ID: 30817702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Rutgeerts P; Feagan BG; Marano CW; Padgett L; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Zhang H; Colombel JF; Reinisch W; Gibson PR; Sandborn WJ;
    Aliment Pharmacol Ther; 2015 Sep; 42(5):504-14. PubMed ID: 26119226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.